Edgewise Therapeutics EWTX Stock
Edgewise Therapeutics Price Chart
Edgewise Therapeutics EWTX Financial and Trading Overview
| Edgewise Therapeutics stock price | 40.3 USD |
| Previous Close | 40.48 USD |
| Open | 41.01 USD |
| Bid | 30.11 USD x 200 |
| Ask | 52.64 USD x 200 |
| Day's Range | 40.42 - 41.94 USD |
| 52 Week Range | 14.25 - 48.51 USD |
| Volume | 1.43M USD |
| Avg. Volume | 1.34M USD |
| Market Cap | 4.5B USD |
| Beta (5Y Monthly) | 0.331 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.86 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.62 USD |
EWTX Valuation Measures
| Enterprise Value | 4.04B USD |
| Trailing P/E | N/A |
| Forward P/E | -22.795599 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 9.9591055 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -18.633 |
Trading Information
Edgewise Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.331 |
| 52-Week Change | 163.71% |
| S&P500 52-Week Change | 14.15% |
| 52 Week High | 48.51 USD |
| 52 Week Low | 14.25 USD |
| 50-Day Moving Average | 42.84 USD |
| 200-Day Moving Average | 34.71 USD |
EWTX Share Statistics
| Avg. Volume (3 month) | 1.34M USD |
| Avg. Daily Volume (10-Days) | 1.96M USD |
| Shares Outstanding | 108.6M |
| Float | 74.27M |
| Short Ratio | 7.99 |
| % Held by Insiders | 0.48% |
| % Held by Institutions | 111.69% |
| Shares Short | 9.54M |
| Short % of Float | 12.37% |
| Short % of Shares Outstanding | 8.79% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.033% |
| Return on Equity (ttm) | -38.031% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -216768992 USD |
| Net Income Avi to Common (ttm) | -197222000 USD |
| Diluted EPS (ttm) | -1.89 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 460.71M USD |
| Total Cash Per Share (mrq) | 4.24 USD |
| Total Debt (mrq) | 3.59M USD |
| Total Debt/Equity (mrq) | 0.8 USD |
| Current Ratio (mrq) | 16.236 |
| Book Value Per Share (mrq) | 4.157 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -158380000 USD |
| Levered Free Cash Flow (ttm) | -92311376 USD |
Profile of Edgewise Therapeutics
| Country | United States |
| State | CO |
| City | Boulder |
| Address | 1715 38th Street |
| ZIP | 80301 |
| Phone | 720 262 7002 |
| Website | https://edgewisetx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 127 |
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Q&A For Edgewise Therapeutics Stock
What is a current EWTX stock price?
Edgewise Therapeutics EWTX stock price today per share is 40.3 USD.
How to purchase Edgewise Therapeutics stock?
You can buy EWTX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Edgewise Therapeutics?
The stock symbol or ticker of Edgewise Therapeutics is EWTX.
Which industry does the Edgewise Therapeutics company belong to?
The Edgewise Therapeutics industry is Biotechnology.
How many shares does Edgewise Therapeutics have in circulation?
The max supply of Edgewise Therapeutics shares is 108.6M.
What is Edgewise Therapeutics Price to Earnings Ratio (PE Ratio)?
Edgewise Therapeutics PE Ratio is now.
What was Edgewise Therapeutics earnings per share over the trailing 12 months (TTM)?
Edgewise Therapeutics EPS is -1.86 USD over the trailing 12 months.
Which sector does the Edgewise Therapeutics company belong to?
The Edgewise Therapeutics sector is Healthcare.
Edgewise Therapeutics EWTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27477.31 USD — |
+1.05
|
7.04B USD — | 27223.49 USD — | 27544.06 USD — | — - | 7.04B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
13524.02 USD — |
+1.07
|
— — | 13397.04 USD — | 13557.29 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7022.12 USD — |
+1.07
|
— — | 6892.36 USD — | 7043.1 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1320 USD — |
+1.33
|
— — | 1298.21 USD — | 1322.56 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}
